Protective role of synthetic oligodeoxynucleotides expressing immunosuppressive TTAGGG motifs in concanavalin A-induced hepatitis

Immunology Letters

Volumn 151, Issue 1-2, 2013, Pages 54-60

  Li, Ning ^a   Liu, Yue Hui ^a   Li, Sha Ling ^a   Fu, Chun Yan ^a   Zhou, Rong Rong ^a,b   Huang, Yan ^a,b   Fan, Xue Gong ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Key Laboratory of Viral Hepatitis   (China)

Author keywords

Concanavalin A; IFN ; IL 4; Liver; Suppressive ODNs; Th1

Indexed keywords

ANTIINFLAMMATORY AGENT; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 4; OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE A151; STAT1 PROTEIN; STAT4 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS; IN VIVO STUDY; LIVER PROTECTION; LYMPHOCYTE DIFFERENTIATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; FEMALE; HEPATITIS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; NUCLEOTIDE MOTIFS; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHORYLATION; STAT4 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS;

EID: 84876311791     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.02.004     Document Type: Article

References (37)

1. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199:201-216.
2. Krieg A.M. The role of CpG motifs in innate immunity. Curr Opin Immunol 2000, 12:35-43.
3. Rudolph K.L., Chang S., Lee H.W., Blasco M., Gottlieb G.J., Greider C., et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1996, 96:701-712.
4. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
5. Gursel I., Gursel M., Yamada H., Ishii K.J., Takeshita F., Klinman D.M. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003, 171:1393-1400.
6. Shirota H., Gursel M., Klinman D.M. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling. J Immunol 2004, 173:5002-5007.
7. Dong L., Ito S., Ishii K.J., Klinman D.M. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum 2004, 50:1686-1689.
8. Shirota H., Gursel I., Gursel M., Klinman D.M. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 2005, 174:4579-4583.
9. Sato T., Shimosato T., Alvord W.G., Klinman D.M. Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation. J Immunol 2008, 180:7648-7654.
10. Dong L., Ito S., Ishii K.J., Klinman D.M. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB×NZW mice. Arthritis Rheum 2005, 52:651-658.
11. Cheng X., Chen Y., Xie J.J., Yao R., Yu X., Liao M.Y., et al. Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance. J Mol Cell Cardiol 2008, 45:168-175.
12. Fujimoto C., Klinman D.M., Shi G., Yin H., Vistica B.P., Lovaas J.D., et al. A suppressive oligodeoxynucleotide inhibits ocular inflammation. Clin Exp Immunol 2009, 156:528-534.
13. Ho P.P., Fontoura P., Platten M., Sobel R.A., DeVoss J.J., Lee L.Y., et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol 2005, 175:6226-6234.
14. Yamashita J., Iwamura C., Sasaki T., Mitsumori K., Ohshima K., Hada K., et al. Apolipoprotein A-II suppressed concanavalin A-induced hepatitis via the inhibition of CD4 T cell function. J Immunol 2011, 186:3410-3420.
15. Ohta A., Sekimoto M., Sato M., Koda T., Nishimura S., Iwakura Y., et al. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol 2000, 165:956-961.
16. Zhang H., Gong Q., Li J.H., Kong X.L., Tian L., Duan L.H., et al. CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice. Int Immunopharmacol 2010, 10:79-85.
17. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000, 97:5498-5503.
18. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z., et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 2002, 110:1503-1513.
19. González-Périz A., Planagumà A., Gronert K., Miquel R., López-Parra M., Titos E., et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J 2006, 20:2537-2539.
20. Bea F., Kreuzer J., Preusch M., Schaab S., Isermann B., Rosenfeld M.E., et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006, 26:2787-2792.
21. Fushimi S., Ogino T., Hara J., Takahata T., Wakabayashi H., Watanabe H., et al. Forced expression of suppressor of cytokine signaling 3 in T cells protects the development of concanavalin A-induced hepatitis in mice. Clin Immunol 2009, 133:437-446.
22. Küsters S., Gantner F., Künstle G., Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996, 111:462-471.
23. Gantner F., Leist M., Lohse A.W., Germann P.G., Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995, 21:190-198.
24. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., Darnell J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76:821-828.
25. Miner K.T., Croft M. Generation, persistence, and modulation of Th0 effector cells: role of autocrine IL-4 and IFN-gamma. J Immunol 1998, 160:5280-5287.
26. Nakamura T., Lee R.K., Nam S.Y., Podack E.R., Bottomly K., Flavell R.A. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type1 and 2 phenotype. J Immunol 1997, 158:2648-2653.
27. Klinman D., Shirota H., Tross D., Sato T., Klaschik S. Synthetic oligonucleotides as modulators of inflammation. Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol 2008, 84:958-964.
28. Matsumoto G., Tsunematsu S., Tsukinoki K., Ohmi Y., Iwamiya M., Oliveira-dos-Santos A., et al. Essential role of the adhesion receptor LFA-1 for T cell-dependent fulminant hepatitis. J Immunol 2002, 169:7087-7096.
29. Tagawa Y., Sekikawa K., Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-gamma (-/-) mice, but not in TNF-alpha (-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol 1997, 159:1418-1428.
30. Kano A., Haruyama T., Akaike T., Watanabe Y. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 1999, 257:672-677.
31. Jaruga B., Hong F., Sun R., Radaeva S., Gao B. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol 2003, 171:3233-3244.
32. Volarevic V., Mitrovic M., Milovanovic M., Zelen I., Nikolic I., Mitrovic S., et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J Hepatol 2012, 56:26-33.
33. Klinman D.M., Gursel I., Klaschik S., Dong L., Currie D., Shirota H. Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs. Ann NY Acad Sci 2005, 1058:87-95.
34. Peng S.L. The T-box transcription factor T-bet in immunity and autoimmunity. Cell Mol Immunol 2006, 3:87-95.
35. Rosen H.R., Miner C., Sasaki A.W., Lewinsohn D.M., Conrad A.J., Bakke A., et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002, 35:190-198.
36. Kita H., Mackay I.R., Van De Water J., Gershwin M.E. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001, 120:1485-1501.
37. Thiele G.M., Freeman T.L., Klassen L.W. Immunologic mechanisms of alcoholic liver injury. Semin Liver Dis 2004, 24:273-287.